NVO
Novo Nordisk A/S Sponsored ADR Class B · BX:NVO
32.29 CHF0.003000 +0.01%
Novo Nordisk A/S Sponsored ADR Class B (BX:NVO) last traded at 32.29 CHF, up 0.01% on the day. Over the past year the stock is down 23.50%. Its 52-week range is 28.79 to 42.21. It is in the Health Technology sector (Pharmaceuticals: Major).
Key statistics
Open32.29
Day range32.29 – 32.29
52-week range28.79 – 42.21
Volume1.50 K
Average volume (10 days)1.10 K
Market cap (USD)175.64 B
P/E9.76
EPS (TTM) (USD)4.09
Dividend yield3.08%
Revenue (TTM) (USD)51.45 B
Employees68.79 K
Performance
−0.13%1 week
+1.83%1 month
−20.46%3 months
−0.38%6 months
+9.90%Year to date
−23.50%1 year
Technical rating
Sell
Daily summary of 11 oscillators and 15 moving averages. See every indicator
Analysts’ target
40.94 CHF
The average 1-year price target, +26.78% from the last price. See the forecast
Latest headlines
- Weekly Recap: Wegovy scripts 265k+ and injunction denied in Eli Lilly ad suitTradingView · 02 Nov 2026
- Stocktwits Pharma Pulse: Biotech Beats The Broader Market — Novo, Pfizer And Moderna Earnings Up NextStocktwits · 02 Nov 2026
- Jobs, Midterm Elections, Apple, Palantir, McDonald's, Moderna, and More to Watch This Week — Barrons.comDow Jones Newswires · 01 Nov 2026
- Healthcare Earnings Scoreboard: 96% beat EPS estimates, 70% post Y/Y earnings growthSeeking Alpha · 31 Oct 2026
- Steve Jobs' Son Says GLP-1 Weight Loss Drugs Could Be Among Most Important Medicines Ever, With Potential Impact on CancerBenzinga · 29 Oct 2026
- Lilly's retatrutide outshines Ozempic on weight loss, blood sugar control in trialReuters · 28 Oct 2026
- Novo Nordisk Loses Court Bid Against Eli Lilly’s Weight-Loss Drug Ads — Judge Says Sales Impact Was Negligible (UPDATED)Benzinga · 28 Oct 2026
- LLY Vs NVO: Lilly’s Retatrutide Beats Novo’s Ozempic In Head-To-Head Trial — Retatrutide More Than Doubles Weight LossStocktwits · 28 Oct 2026
Market data from TradingView’s public feed, delayed as the exchange requires. For study only, not investment advice.